Futurity · Health

New MRI Contrast Agent Shows Promise for Early Lung Cancer Detection

Researchers developed a novel protein-based MRI contrast agent that detects invasive lung cancer and metastases earlier than current methods, potentially improving diagnosis and treatment.

The precision MRI method, in Science Advances, identifies tumors and metastases as small as 1 millimeter. It aims to detect lung cancer before it spreads, without radiation exposure.

The agent, hProCA32.Collagen, targets collagen type I, elevated in aggressive tumors. Preclinical studies showed it could detect small tumors and metastases in lungs and other organs.

This biomarker-targeting approach enhances detection of early-stage cancer cells. It proved effective in aggressive lung adenocarcinomas prone to spreading.

The research, a collaboration including Georgia State University, visualized invasive lung cancer and its spread earlier than previously possible.

The technology may aid personalized treatment by visualizing collagen remodeling, potentially identifying high-risk patients and guiding therapy.

The findings suggest precision MRI can detect tiny tumors and metastases without radiation, offering clues about cancer aggressiveness. A company is advancing this technology toward clinical use and FDA application.

AI-samenvatting op basis van de bron.